Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain

NCT ID: NCT00236327

Last Updated: 2011-05-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 34 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-06-30
• Study Completion Date: 2004-05-31

Brief Summary

The purpose of this study is to determine the safety and efficacy of pain control by fentanyl, administered via adhesive skin patches, at doses of 25 to 100 micrograms per hour in 80 out-patients with intense chronic cancer pain. Higher doses are allowed by permission of the investigator and rescue oral morphine medication is allowed.

Detailed Description

Patients with cancer pain are frequently under-medicated with morphine. This is a 56-day open-label study of the efficacy and safety of self-administered fentanyl skin patches for cancer pain control in patients in the home-care setting not previously using morphine. The first 15 days of the study are for dose stabilization and the rest of the study assesses pain control and quality of life at stable doses of medication. The dose is determined by the patient with oversight by the investigator, and rescue oral morphine medication can be used when necessary. The patient records all medication use in a diary and fills out questionnaires concerning pain control, intestinal function (constipation) and overall quality of life. The hypothesis is that patients will be able to control their cancer pain by self-administering transdermal fentanyl at home and that they will well tolerate the medication.

Individualized doses, with a target dose of 25 to 100 micrograms per hour of fentanyl for 56 days via skin patches applied every 3 days to deliver 25 to 100 micrograms of fentanyl per hour per patch; oral morphine as rescue medication for pain.

Conditions

Pain

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

fentanyl

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Less than a month of opioid treatment over the past 3 months
• Proven cancer and chronic stable, cancer-related pain
• Pain control medication (aside from opioids) at the maximum authorized dose in the 24-hours preceding the first study visit
• A pain score of at least 4 on the VAS scale and pain that justifies intervention by opium-derived drugs in the opinion of the investigator

Exclusion Criteria

• Liver or kidney problems
• Previous heart, lung or nervous disorders
• Allergy to fentanyl
• Skin condition that might interfere with absorption of the fentanyl through the skin
• Surgery or chemotherapy in the month preceding the study or scheduled during the 56 days of the study
• History of substance abuse

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen Cilag S.A.S.

INDUSTRY

Sponsor Role: lead

Principal Investigators

Janssen-Cilag S.A.S. Clinical Trial

Role: STUDY_DIRECTOR

Janssen Cilag S.A.S.

Related Links

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=272&filename=CR002920_CSR.pdf

Assessment of the efficacy and tolerance of transdermal fentanyl in patients with chronic cancer pain in outpatient medicine

Other Identifiers

CR002920

Identifier Type: -

Identifier Source: org_study_id